These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14755031)

  • 1. The potential epidemiological impact of a genital herpes vaccine for women.
    Garnett GP; Dubin G; Slaoui M; Darcis T
    Sex Transm Infect; 2004 Feb; 80(1):24-9. PubMed ID: 14755031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological impact of a genital herpes type 2 vaccine for young females.
    Lou Y; Qesmi R; Wang Q; Steben M; Wu J; Heffernan JM
    PLoS One; 2012; 7(10):e46027. PubMed ID: 23071536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
    Spicknall IH; Looker KJ; Gottlieb SL; Chesson HW; Schiffer JT; Elmes J; Boily MC
    Vaccine; 2019 Nov; 37(50):7396-7407. PubMed ID: 29625767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines.
    Schwartz EJ; Bodine EN; Blower S
    Hum Vaccin; 2007; 3(6):231-8. PubMed ID: 17881889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.
    Alsallaq RA; Schiffer JT; Longini IM; Wald A; Corey L; Abu-Raddad LJ
    Sex Transm Dis; 2010 May; 37(5):290-7. PubMed ID: 20351622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
    Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
    N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes simplex virus type 2 infection in young adult women: risk factors for infection and frequency of viral shedding.
    Fife KH; Williams JA; Thomas AL; Ofner S; Katz BP; Fortenberry JD
    Sex Transm Dis; 2010 Apr; 37(4):248-52. PubMed ID: 20216477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy results of a trial of a herpes simplex vaccine.
    Belshe RB; Leone PA; Bernstein DI; Wald A; Levin MJ; Stapleton JT; Gorfinkel I; Morrow RL; Ewell MG; Stokes-Riner A; Dubin G; Heineman TC; Schulte JM; Deal CD;
    N Engl J Med; 2012 Jan; 366(1):34-43. PubMed ID: 22216840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of genital herpes infections.
    Mertz GJ
    Infect Dis Clin North Am; 1993 Dec; 7(4):825-39. PubMed ID: 8106731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genital shedding of herpes simplex virus among men.
    Wald A; Zeh J; Selke S; Warren T; Ashley R; Corey L
    J Infect Dis; 2002 Oct; 186 Suppl 1():S34-9. PubMed ID: 12353185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition.
    Wald A; Krantz E; Selke S; Lairson E; Morrow RA; Zeh J
    J Infect Dis; 2006 Jul; 194(1):42-52. PubMed ID: 16741881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
    Leone P
    Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of genital herpes - recent advances.
    Halioua B; Malkin JE
    Eur J Dermatol; 1999; 9(3):177-84. PubMed ID: 10210781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genital herpes vaccines--cause for cautious optimism.
    Haddow LJ; Mindel A
    Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.